secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001013762-25-001844
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M
--------------------------------------------------------------------------------

- Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.
- Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.
- Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.
- Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.
- Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/0001013762-25-001844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-001844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer